Nutriband and Kindeva have completed commercial-scale manufacturing for AVERSA(TM) Fentanyl, a major milestone in the path to FDA approva ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon ...

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more ...

Kerala, often lauded for its literacy and health indices, is now battling an alarming drug abuse crisis that threatens its ...

Nutriband Inc. joins multiple Russell indexes, reflecting its market growth and focus on developing its AVERSA abuse-deterrent technology.

Since day one, a policy priority of the Administration has been to discourage and prevent gender-affirming care for children ...

The 9-year-old from Vietnam was abused by her mother for customers watching on smartphone apps in the U.S. and elsewhere. The mother said she needed the money.

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with ...

Nutriband declares a 25% preferred stock dividend for common shareholders as it advances AVERSA fentanyl product toward FDA approval.

Healing House in Kansas City receives $300,000 from Missouri’s opioid settlement to expand services for families of people in recovery.